Chinese vaccine maker CanSino Biologics' sign on its building in Tianjin on November 20, 2018. Photo Reuters Chinese vaccine maker CanSino Biologics' sign on its building in Tianjin on November 20, 2018. Photo Reuters
Chinese vaccine maker CanSino Biologics' sign on its building in Tianjin on November 20, 2018. Photo Reuters

Coronavirus vaccine developer CanSino offers shares in China’s second-most expensive initial public offering

  • CanSino has priced the A shares of its secondary listing at 209.71 yuan each, the second-most expensive offering price on the mainland’s bourses
  • Hong Kong-traded shares of CanSino more than tripled this year on prospects of the Covid-19 vaccine

Topic |   Coronavirus vaccine
Chinese vaccine maker CanSino Biologics' sign on its building in Tianjin on November 20, 2018. Photo Reuters Chinese vaccine maker CanSino Biologics' sign on its building in Tianjin on November 20, 2018. Photo Reuters
Chinese vaccine maker CanSino Biologics' sign on its building in Tianjin on November 20, 2018. Photo Reuters
READ FULL ARTICLE